Treatment of age-related macular degeneration

1. A compound of the formula:

either as the racemate or the R-enantiomer,

and one or two of R 1 (C═O)—, R 2 (C═O)—, R 3 (C═O)— may be replaced by H, wherein R 1 , R 2 and R 3 may be the same or different and represent

wherein X and Y are independently S, 0, N, NR 8

A represents H or —(C═O) OR B , and when A is H, the compound may form a pharmaceutically acceptable acid salt;

R 5 , R 6 , R 7 independently represent H, F, Cl, CF 3 , Br, I, alkyl of 1 to 6 carbons branched or unbranched, or chains of 3 to 5 atoms including C, N, S, 0, with or without bonds double, with or without attached R 5 , R 6 , R 7 groups, which may comprise two adjacent R 5 , R 6 , or R 7 groups to form a closed ring; and R 8 is an alkyl group of 1-10 carbon atoms which may be branched or straight chain.

2. The compound of claim 1 , wherein said pharmaceutically acceptable acid salt is selected from the group consisting of a hydrochloric, hydrobromic, methanesulfonic, alkyl sulfonic acid of 1 to 4 carbon atoms branched or unbranched, arylsulfonic, aryl or heteroaryl carboxylic acid salt.

3. The compound of claim 1 , wherein said pharmaceutically acceptable acid salt is a salt of an alkanoic acid of 2-6 carbons unbranched or branched.

4. The compound of claim 1 in which R 1 , R 2 , R 3 represent a phenyl or naphthyl (1- or 2-) moiety, substituted with one or more of said R 5 , R 6 , R 7 groups.

5. The compound 6-Chloro-7,8-dibenzoyloxy-1-(p-benzoyloxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride.

6. A method for treating dry age-related macular degeneration in a patient in need thereof, the method comprising administering to said patient a therapeutically effective amount of a compound as claimed in claim 1 .

7. The method of claim 6 , wherein the R-enantiomer of said compound is administered to said patient.